José Ramón Arribas López

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week Results

D. Cooper, B. Conway, S. Chuck, 2013, Journal of acquired immune deficiency syndromes.